Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Folate receptor alpha in platinum-resistant ovarian cancer: prevalence in a multicenter Polish cohort and review of the evidence.
Jędrzej Borowczak, Justyna Durślewicz, Monika Durzyńska, Jakub Cheliński, Maria Filipek, Marek Zdrenka, Łukasz Szylberg
Published: 202510.1007/s12094-025-04179-3
Abstract
BACKGROUND: Folate receptor alpha (FRα, FOLR1) is the required biomarker for mirvetuximab soravtansine, a treatment option for patients with platinum-resistant ovarian cancer. Since its approval, the drug has been introduced into national drug progra…
Preview only. Read the full abstract at the source